Eurofins Scientific SE · EURONEXT:ERF
Eurofins Scientific — 9M 2022 Earnings Presentation
11 slides from Eurofins Scientific's earnings presentation, Oct 18, 2022
Slide 1: 9M 2022 Trading Update
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific SE and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on in
Slide 3: Key financial and operational highlights
Key financial and operational highlights Reported Revenues Key Highlights • Record-high 9M 2022 revenues driven by steady organic growth and acquisitions that more than compensated for the year-on-year decrease in revenues from COVID-19 testing and reagents of €5,033m +2.7% approximately €500m vs. 9
Slide 4: Significant scientific advances to monitor and improve health
Significant scientific advances to monitor and improve health Outside of COVID-19 testing, Eurofins remains an important contributor to improving human health: o Eurofins Belgium NV has begun carrying out the largest European biomonitoring project for PFAS in blood in Antwerp, commissioned by the Ag
Slide 5: TruGraf Liver, the first and only gene expression diagnostic test
TruGraf Liver, the first and only gene expression diagnostic test to optimise immunosuppression in liver transplant recipients The liver transplant market Current Patient Care liver transplants 1 >10k performed annually in the US $1M cost per liver transplant • Liver function tests • Gene expression
Slide 6: Eurofins Sustainability Solutions Launched
Eurofins Sustainability Solutions Launched Eurofins Sustainability Solutions bring together a wide range of Eurofins companies’ sustainability offerings in one place and enable global customers to benefit from the Eurofins network’s market leading solutions to contribute to product and enterprise su
Slide 7: Outlook
Outlook Eurofins is confirming its objectives for 2022 and plans to update its objectives for 2023 and 2024 when publishing its FY 2022 results on 22 February 2023. By then, the potential impacts of the war in Ukraine, supply chain disruptions, ongoing/permanent COVID-19 testing, inflation and forei
Slide 8: Q&A
Q&A CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 8
Slide 9: Appendix
Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 9
Slide 10: Breakdown of Revenue by Operating Segment
Breakdown of Revenue by Operating Segment €m 9M 2022 As % of total 9M 2021 As % of total Growth % Europe 2,651 52.7% 2,939 60.0% -9.8% North America 1,851 36.8% 1,557 31.8% 18.9% Rest of the World 531 10.6% 406 8.3% 30.7% Total 5,033 100.0% 4,902 100.0% 2.7% €m Q3 2022 As % of total Q3 2021 As % of
Slide 11: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) Eurofins is providing in the consolidated financial statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results – reflect the ongoing performance of the mature and re